The Berke Report
CDMO & Manufacturing
Second Week of April 2023

Berke EXECUTIVE SEARCH
Berkesearch.com

Contact Carl Berke For More Information Carl@Berkesearch.com

- 04.14.23 - Wheeler Bio Announces Closing of $31 Million Series A Round Supporting its Clinical Drug Substance Manufacturing Facility in Oklahoma City (PR)
  - Wheeler Bio, Inc., a boutique contract development and manufacturing organization (CDMO) specializing in process development and small batch CGMP production of therapeutic antibodies, announced the closing of their Series A financing round. The round was co-led by Charles River Laboratories and Echo with participation from ATUM, Floating Point Advisors, Pine Ridge Ventures, Plains Venture Partners (a subsidiary of i2E), Seagull Capital, and Alloy Therapeutics. Wheeler Bio is building a disruptive CDMO model that is changing the paradigm for the gene-to-IND supply chain. Their primary service offering, Portable CMC, is an open source 'CMC middleware' that delivers speed, efficiency, predictability, and freedom to operate by integrating discovery CROs and CDMOs and effectively bridging the translational gap.
- 04.12.23 - Societal CDMO Signs Multiple Project Expansion Agreements With Existing Customers (PR)
  - Societal CDMO announced that it has signed work order extensions with multiple existing customers that span a variety of the company's CDMO service areas of expertise. The expansion of the scope of work of existing customers continues to be a strategic area of growth for the company, complementing its parallel efforts dedicated to the securing of new customers.
- 04.11.23 - Cell Therapy Pioneers Team Up to Found Viral Vector CDMO Backed by $64M (medcitynews)
  - VintaBio manufactures AAV and lentiviral vectors for entities pursuing clinical development of cell and gene therapies. The contract development manufacturing organization's launch comes as demand for viral vectors continues to outpace the supply of these crucial components of the therapies. VintaBio was co-founded by Junwei Sun and Shangzhen Zhou, both of them University of Pennsylvania researchers who were key to the development of the CAR T-cell therapy that became Kymriah, the Novartis product that was the first FDA-approved cell therapy. They were also involved in the research that led to the first two FDA-approved gene therapies, Luxturna from Spark Therapeutics and Zolgensma from Novartis.
- 04.11.23 - Alcami Doubles Site's Sterile Vial Production With New Line (healthcarepackaging)
  - Headquartered in Wilmington, N.C., Alcami, a major CDMO for the pharmaceutical and biotech industries, has facilities across the U.S., including scientific campuses in Charleston, S.C.; Research Triangle Park, N.C.; St. Louis, Mo.; and multiple locations near Boston. Icami's new ARF isolator line is up and running, allowing the company to fill 2 mlliliter vials at an output of over 6,000 vials/hr, more than doubling the daily production volume in Charleston, while complementing four sterile fill/finish lines in North Carolina.
- 04.11.23 - Catalent breaks ground on $20M expansion of clinical supply facility (fiercepharma)
  - Catalent broke ground on a $20 million expansion of the CDMO giant's clinical supply facility in Germany. The project is expected to increase the Schorndorf site's footprint by 32,000 square feet, adding additional storage for clinical supplies that need to be kept at temperatures between 15 and 25 degrees Celsius (59 to 77 degrees Fahrenheit). With the expansion, the company is also plotting space for its FastChain supply service designed to improve regional supply of clinical materials. In addition, Catalent is planning to add an automatic bottle filling line at the site, the company said in an April 6 press release.